Peripheral nervous system involvement accompanies central nervous system involvement in anti-glial fibrillary acidic protein (GFAP) antibody-related disease.
Autoimmune encephalitis
ENMG
GFAP
Peripheral neuropathy
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
18
05
2023
accepted:
26
07
2023
revised:
25
07
2023
medline:
23
10
2023
pubmed:
4
8
2023
entrez:
4
8
2023
Statut:
ppublish
Résumé
Glial fibrillary acidic protein (GFAP) is expressed by astrocytes in the central nervous system (CNS), but also by immature and regenerative Schwann cells in the peripheral nervous system (PNS). GFAP antibodies (GFAP-Abs) in cerebrospinal fluid (CSF) have been mainly described in patients with meningoencephalomyelitis. We aimed to study PNS symptoms in patients with CSF GFAP-Abs. We retrospectively included all patients tested positive for GFAP-Abs in the CSF by immunohistochemistry and confirmed by cell-based assay expressing human GFAPα since 2017, from two French reference centers. In a cohort of 103 CSF GFAP-Abs patients, 25 (24%) presented with PNS involvement. Among them, the median age at onset was 48 years and 14/25 (56%) were female. Abnormal electroneuromyography was observed in 11/25 patients (44%), including eight isolated radiculopathies, one radiculopathy associated with polyneuropathy, one radiculopathy associated with sensory neuronopathy, and one demyelinating polyradiculoneuropathy. Cranial nerve involvement was observed in 18/25 patients (72%). All patients except one had an associated CNS involvement. The first manifestation of the disease concerned the PNS in three patients. First-line immunotherapy was administered to 18/24 patients (75%). The last follow-up modified Rankin Scale was ≤ 2 in 19/23 patients (83%). Patients with PNS involvement had significantly more bladder dysfunction than patients with isolated CNS involvement (68 vs 40.3%, p = 0.031). PNS involvement in GFAP-Abs autoimmunity is heterogeneous but not rare and is mostly represented by acute or subacute cranial nerve injury and/or lower limb radiculopathy. Rarely, PNS involvement can be the first manifestation revealing the disease.
Sections du résumé
BACKGROUND
BACKGROUND
Glial fibrillary acidic protein (GFAP) is expressed by astrocytes in the central nervous system (CNS), but also by immature and regenerative Schwann cells in the peripheral nervous system (PNS). GFAP antibodies (GFAP-Abs) in cerebrospinal fluid (CSF) have been mainly described in patients with meningoencephalomyelitis. We aimed to study PNS symptoms in patients with CSF GFAP-Abs.
METHODS
METHODS
We retrospectively included all patients tested positive for GFAP-Abs in the CSF by immunohistochemistry and confirmed by cell-based assay expressing human GFAPα since 2017, from two French reference centers.
RESULTS
RESULTS
In a cohort of 103 CSF GFAP-Abs patients, 25 (24%) presented with PNS involvement. Among them, the median age at onset was 48 years and 14/25 (56%) were female. Abnormal electroneuromyography was observed in 11/25 patients (44%), including eight isolated radiculopathies, one radiculopathy associated with polyneuropathy, one radiculopathy associated with sensory neuronopathy, and one demyelinating polyradiculoneuropathy. Cranial nerve involvement was observed in 18/25 patients (72%). All patients except one had an associated CNS involvement. The first manifestation of the disease concerned the PNS in three patients. First-line immunotherapy was administered to 18/24 patients (75%). The last follow-up modified Rankin Scale was ≤ 2 in 19/23 patients (83%). Patients with PNS involvement had significantly more bladder dysfunction than patients with isolated CNS involvement (68 vs 40.3%, p = 0.031).
CONCLUSIONS
CONCLUSIONS
PNS involvement in GFAP-Abs autoimmunity is heterogeneous but not rare and is mostly represented by acute or subacute cranial nerve injury and/or lower limb radiculopathy. Rarely, PNS involvement can be the first manifestation revealing the disease.
Identifiants
pubmed: 37540278
doi: 10.1007/s00415-023-11908-7
pii: 10.1007/s00415-023-11908-7
pmc: PMC10576672
doi:
Substances chimiques
Glial Fibrillary Acidic Protein
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5545-5560Subventions
Organisme : Agence Nationale de la Recherche
ID : ANR-18-RHUS-0012
Informations de copyright
© 2023. The Author(s).
Références
Prog Neurobiol. 2011 Mar;93(3):421-43
pubmed: 21219963
J Neuroimmunol. 1985 Jun;8(4-6):311-30
pubmed: 3891780
J Neurol Neurosurg Psychiatry. 2018 Feb;89(2):138-146
pubmed: 28951498
J Neuroimmunol. 2018 Aug 15;321:157-163
pubmed: 29793728
J Neurol Neurosurg Psychiatry. 2015 Dec;86(12):1347-55
pubmed: 25628376
Eur J Neurol. 2018 Mar;25(3):477-483
pubmed: 29193473
Mult Scler Relat Disord. 2020 Jan 3;39:101924
pubmed: 31927153
Brain Res. 1992 Jan 20;570(1-2):209-17
pubmed: 1617413
J Neurol Neurosurg Psychiatry. 2020 Jan;91(1):49-57
pubmed: 31690697
Ther Adv Neurol Disord. 2023 Apr 7;16:17562864231164806
pubmed: 37057197
J Neuroimmunol. 2019 Jul 15;332:91-98
pubmed: 30991306
Brain. 2009 Jul;132(Pt 7):1723-33
pubmed: 19506068
Curr Opin Neurol. 2017 Oct;30(5):513-520
pubmed: 28682959
J Cell Sci. 2006 Oct 1;119(Pt 19):3981-93
pubmed: 16988027
Lancet. 2016 Aug 13;388(10045):717-27
pubmed: 26948435
J Neuroimmunol. 2020 Jun 15;343:577233
pubmed: 32272393
Ann Neurol. 2017 Feb;81(2):298-309
pubmed: 28120349
Curr Infect Dis Rep. 2017 Jan;19(1):1
pubmed: 28102519
J Neurocytol. 1984 Apr;13(2):187-200
pubmed: 6726286
Rev Neurol (Paris). 2019 Sep - Oct;175(7-8):420-426
pubmed: 31371185
J Neuroimmunol. 1985 Jun;8(4-6):377-93
pubmed: 3891784
Neurology. 2022 Feb 8;98(6):e653-e668
pubmed: 34799461
Neurol Neuroimmunol Neuroinflamm. 2021 Jul 28;8(5):
pubmed: 34321331
JAMA Neurol. 2016 Nov 01;73(11):1297-1307
pubmed: 27618707
Neurol Sci. 2022 Nov;43(11):6583-6584
pubmed: 35792971
Eur J Neurol. 2021 Nov;28(11):3556-3583
pubmed: 34327760
Neuroophthalmology. 2016 Jan 30;40(1):23-27
pubmed: 27928378
Medicine (Baltimore). 2021 Jun 25;100(25):e26448
pubmed: 34160439